Multi-disciplinary team seeks to better understand mechanisms of radiation therapy
Our oncologists have compiled the top 10 abstracts recently presented at the annual meeting of the
American Society of Clinical Oncology.
New research reinforces the safety and efficacy of combination treatment with nivolumab, gemcitabine and cisplatin in patients with muscle-invasive bladder cancer.
A new study found higher rates of mortality and worse oncologic outcomes in bladder cancer patients residing in more socioeconomically disadvantaged neighborhoods who underwent radical cystectomy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services Policy
Prescribing patterns show that an increasing number of patients with locally advanced or metastatic urothelial carcinoma are being treated with systemic therapy.
Tumor mutational burden may help predict the response to immune checkpoint inhibitors in patients with metastatic urothelial carcinoma who are ineligible for chemotherapy.
Cleveland Clinic surgeons are utilizing minimally invasive techniques and investigating new approaches to improve bladder cancer outcomes.
Findings from a new study help clarify the role of neoadjuvant chemotherapy in the management of bladder cancer with variant histology.
A prototype blood-based screening test evaluated by Cleveland Clinic researchers and others can accurately detect and localize multiple types of cancer, often before symptoms show. The promising results raise hopes that the assay will help achieve the long-sought goal of population-scale early detection of cancer.
A new Cleveland Clinic study documents the impacts that shortages of the immunotherapy agent Bacillus Calmette-Guerin have had on clinical management of non-muscle invasive bladder cancer. Urologic oncologist Robert Abouassaly, MD, discusses the findings and implications.